Endospan

Executive Summary

Endospan is a private Israeli med-tech company developing the NEXUS platform, a custom-made, multi-branch endovascular stent graft system for minimally invasive repair of aortic arch aneurysms and dissections. The technology addresses a critical unmet need for patients who are poor candidates for conventional open surgery or standard EVAR/TEVAR due to complex aortic arch anatomy. With the global aortic aneurysm market expected to exceed $5 billion by 2030, Endospan’s personalized approach could capture a significant share of the arch repair segment. The company has advanced its NEXUS system through Phase 2 clinical studies, demonstrating procedural safety and feasibility. Key upcoming milestones include completion of enrollment in its pivotal trial (expected Q4 2026) and potential FDA Breakthrough Device designation, which could accelerate regulatory review. With a strong intellectual property portfolio and an experienced management team, Endospan is well-positioned to become a leader in endovascular aortic arch therapy.

Upcoming Catalysts (preview)

• Q4 2026Completion of Pivotal Trial Enrollment70% success
• Q2 2026FDA Breakthrough Device Designation50% success
• Q3 2027CE Mark Submission60% success